MARINUS PHARMACEUTICALS
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings. The company was founded in 2003 and is based in Branford, Connecticut.
MARINUS PHARMACEUTICALS
Industry:
Biopharma Biotechnology Health Diagnostics Pharmaceutical Therapeutics
Founded:
2003-01-01
Address:
Branford, Connecticut, United States
Country:
United States
Website Url:
http://www.marinuspharma.com
Total Employee:
101+
Status:
Active
Contact:
484-253-6792
Email Addresses:
[email protected]
Total Funding:
314.37 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Oaktree Capital Management
Oaktree Capital Management investment in Post-IPO Debt - Marinus Pharmaceuticals
Oaktree Capital Management
Oaktree Capital Management investment in Post-IPO Debt - Marinus Pharmaceuticals
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Post-IPO Equity - Marinus Pharmaceuticals
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Post-IPO Equity - Marinus Pharmaceuticals
Canaan Partners
Canaan Partners investment in Series C - Marinus Pharmaceuticals
Domain Associates
Domain Associates investment in Series C - Marinus Pharmaceuticals
Foundation Medical Partners
Foundation Medical Partners investment in Series C - Marinus Pharmaceuticals
Sofinnova Investments
Sofinnova Investments investment in Series C - Marinus Pharmaceuticals
RMI Partners
RMI Partners investment in Venture Round - Marinus Pharmaceuticals
Sofinnova Investments
Sofinnova Investments investment in Series B - Marinus Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2020-06-15 | Marinus Pharmaceuticals Appoints Martha Manning as Vice President, General Counsel and Secretary |
Official Site Inspections
http://www.marinuspharma.com Semrush global rank: 3.75 M Semrush visits lastest month: 3.6 K
- Host name: 192.86.185.35.bc.googleusercontent.com
- IP address: 35.185.86.192
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Marinus Pharmaceuticals" on Search Engine
Marinus Pharmaceuticals, Inc. - Marinus Pharmaceuticals …
Apr 15, 2024 RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative …See details»
Marinus Pharmaceuticals - Crunchbase Company Profile …
About. Marinus Pharmaceuticals reformulates, develops, and commercializes drugs to treat neurological, psychiatric, and pain disorders. Branford, Connecticut, United States. …See details»
Marinus Pharmaceuticals, Inc. - Marinus Pharmaceuticals to …
2 days ago Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure …See details»
Marinus Pharma | LinkedIn
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. site. …See details»
Marinus Pharmaceuticals, Inc. - Marinus Pharmaceuticals …
Dec 31, 2023 RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative …See details»
FDA approves new epilepsy drug, handing Marinus a long …
Mar 21, 2022 The treatment, which will be sold by Pennsylvania-based Marinus Pharmaceuticals under the brand name Ztalmy, is approved specifically for patients two …See details»
Marinus Pharmaceuticals Provides Business Update and Reports …
Nov 7, 2022 RADNOR, Pa.-- ( BUSINESS WIRE )-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative …See details»
Marinus Pharmaceuticals, Inc. - Marinus Pharmaceuticals …
Sep 19, 2023 RADNOR, Pa.-- (BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative …See details»
Join Our Team - Marinus Pharmaceuticals
At Marinus, we are committed to making a meaningful difference in the lives of patients and families with seizure disorders. Come join us! Explore Open Positions. Culture & Values. …See details»
Support & Sponsorship - Marinus Pharmaceuticals
As part of our commitment to improving the lives of patients living with seizure disorders, we recognize the value of supporting the healthcare and patient community by providing …See details»
Marinus Pharmaceuticals to Present at the RBC Capital Markets …
1 day ago Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today …See details»
Marinus Pharmaceuticals Provides Update on the Phase 3
Apr 15, 2024 Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure …See details»
Marinus Pharmaceuticals, Inc. - News
Apr 5, 2024 Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024. Download. February 16, …See details»
Marinus Pharmaceuticals, Inc. - Marinus Pharmaceuticals to …
Feb 20, 2024 Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure …See details»
Marinus Pharmaceuticals - Funding, Financials, Valuation
Funding. Marinus Pharmaceuticals has raised a total of. $451.9M. in funding over 13 rounds. Their latest funding was raised on Nov 7, 2022 from a Post-IPO Equity round. …See details»
Marinus Pharmaceuticals, Inc. (MRNS) - Yahoo Finance
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic …See details»
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 …
Nov 8, 2023 Marinus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.61, expectations were $-0.67. Operator: Greetings and welcome to the Marinus …See details»
Organization | Marinus Pharmaceuticals - CDEK
Organization Overview. First Clinical Trial. 2007 NCT00442104. First Marketed Drug. 2022 ganaxolone . First NDA Approval ... MARINUS | Marinus Pharmaceuticals | Marinus …See details»
Marinus Pharmaceuticals - Contacts, Employees, Board …
About. Marinus Pharmaceuticals has 9 current employee profiles, including Vice President of Research and Preclinical Development Michael S. Saporito. Marinus …See details»